ALNOV:EPA
Novacyt SA
0,44 €
arrow_upward
+1,38%(+0,0060) 1D
18. stu, 17:35:20 GMT+1 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za ALNOV...
Otvori
0,44 €
Najviša
0,44 €
Najniža
0,43 €
Trž. kap.
32,30 mil.
Prosj. kol.
139,48 tis.
Količina
150,99 tis.
52-tjed. najviša
1,04 €
52-tjed. najniža
0,29 €
EPS
−0,38 €
Dionice u optjecaju
72,59 mil.
Broj djelatnika
228
Otvori
0,44 €
Najviša
0,44 €
Najniža
0,43 €
Trž. kap.
32,30 mil.
Prosj. kol.
139,48 tis.
Količina
150,99 tis.
52-tjed. najviša
1,04 €
52-tjed. najniža
0,29 €
EPS
−0,38 €
Dionice u optjecaju
72,59 mil.
Broj djelatnika
228
Vijesti
Iz web-izvora i od partnera za vijesti
Invezz
·
prije 49 minuta
UBS predicts S&P 500 moving up 12% in 2027 but flags major risks around AI
24/7 Wall St.
·
prije 39 minuta
S&P 500 Slides 0.6% at Midday as the Dow Drops Over 1%
TradingView
·
prije 2 sata
S&P 500, Nasdaq find footing as Nvidia treads water
JournalArta
·
prije 44 minute
S&P 500 Futures Rise After Nvidia Raises Sales Forecast
Profil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA – informacije
Glavni izvršni direktorDavid Allmond
Zaposlenici228
Osnovano3. srp 2006.
Sjedište-
SektorHealth Care
Djelatnost-
Web-lokacijanovacyt.com